Theolytics Announces Appointment of Immatics’ Carsten Reinhardt to its Board of Directors

Carsten Reinhardt

Oxford, UK, 21st September 2020 – Theolytics, a biotech focused on developing curative cancer therapies in the form of best-in-class oncolytic viruses, today announced the Board appointment of Carsten Reinhardt MD PhD.

Dr Reinhardt is a visionary oncology and biotech expert, with extensive experience in translational development and early and late-stage clinical trial design, progressing multiple biological compounds from early preclinical development through first-in-man studies towards approvals in the US and Europe. This includes bringing over 20 new compounds to IND stage, achieving various successful BLA filings, and, at Hoffmann-La Roche, having global responsibility for the development of Herceptin ®. He also has a significant track record in financing biopharmaceutical companies, including successful public offerings (over USD 700m raised in private and public financing rounds) and has been instrumental in numerous deals with large pharmaceutical and biotech companies, achieving repeated deal values over USD 1bn. Further, Dr. Reinhardt, as Chair of the Advisory Board, was instrumental in the acquisition of oncolytic company Vira Therapeutics by Boehringer Ingelheim for up to EUR 210m.

CEO and co-founder Charlotte Casebourne said, “I am delighted that Carsten is joining our Board. His exceptional track-record in the immuno-oncology space, global clinical development and launch expertise, and financing track record brings a wealth of expertise to Theolytics. Carsten’s contribution will be invaluable to us as we work to provide effective therapies for patients.

Our revolutionary approach – harnessing Darwinian selection to optimise viruses as efficacious therapies, suitable for IV delivery – could transform treatment for cancers that are notoriously resistant to existing treatment options.”

Dr Reinhardt, currently Chief Development Officer and Managing Director of NASDAQ-listed Immatics Biotechnologies GmbH said, “I very much look forward to working with Theolytics, a company that is revolutionizing the discovery and development of more effective and safer oncolytic virus therapies. The company’s revolutionary adenoviral-based selection platform enables a target product profile led, highly specific approach to drug discovery and may overcome many of the current limitations of immunooncology.”

Dr Reinhardt joins Theolytics’ world-class team, which includes Chair, Dr Ken Powell, advisors Annalisa Jenkins, Susan Clement-Davies, and Co-founder/SAB Chair Professor Len Seymour.